Eli Lilly rise after reaching distribution deal with Indian drugmaker Cipla

Cipla

23/10/2025 16:29

** Shares of Eli Lilly LLY.N rises to 0.73% to $817.82 on Thursday after it signed a distribution agreement with Indian drugmaker Cipla CIPL.NS to sell weight-loss drugs in the country

** LLY is on track for second straight session of gains and is set for highest close in one week

** Under the agreement, LLY will manufacture the drug and Cipla will market it under the brand name Yurpeak, the drugmakers said

** Yurpeak will be available as a once-weekly pre-filled injector pen, same as Lilly's Mounjaro Kwikpen, allowing healthcare providers to personalise treatment plans to individual patient needs

** Among 32 analysts covering LLY, avg rating is "BUY" and median PT is $900

** LLY is up 6% YTD versus ~6% gain in the S&P 500 health index .SPXHC

 (Reporting by Chibuike Oguh in New York)

 ((Email: Chibuike.Oguh@thomsonreuters.com; Phone: +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net))